GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amneal Pharmaceuticals Inc (FRA:2DT) » Definitions » Profitability Rank

Amneal Pharmaceuticals (FRA:2DT) Profitability Rank : 5 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Amneal Pharmaceuticals Profitability Rank?

Amneal Pharmaceuticals has the Profitability Rank of 5.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Amneal Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2024 was 12.63%. As of today, Amneal Pharmaceuticals's Piotroski F-Score is 5.


Competitive Comparison of Amneal Pharmaceuticals's Profitability Rank

For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amneal Pharmaceuticals's Profitability Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Amneal Pharmaceuticals's Profitability Rank falls into.



Amneal Pharmaceuticals Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Amneal Pharmaceuticals has the Profitability Rank of 5.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Amneal Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=76.576 / 606.456
=12.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Amneal Pharmaceuticals has an F-score of 5 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Amneal Pharmaceuticals Profitability Rank Related Terms

Thank you for viewing the detailed overview of Amneal Pharmaceuticals's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Amneal Pharmaceuticals (FRA:2DT) Business Description

Traded in Other Exchanges
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products, Specialty products, and AvKARE. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and the Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies.

Amneal Pharmaceuticals (FRA:2DT) Headlines

No Headlines